Boston Scientific Corp (BSX)vsCarnival Plc ADS (CUK)
BSX
Boston Scientific Corp
$69.78
+2.39%
HEALTHCARE · Cap: $101.28B
CUK
Carnival Plc ADS
$25.68
+1.18%
CONSUMER CYCLICAL · Cap: $35.08B
Smart Verdict
WallStSmart Research — data-driven comparison
Carnival Plc ADS generates 33% more annual revenue ($26.62B vs $20.07B). BSX leads profitability with a 14.4% profit margin vs 10.4%. BSX appears more attractively valued with a PEG of 0.75. CUK earns a higher WallStSmart Score of 69/100 (B-).
BSX
Buy63
out of 100
Grade: C+
CUK
Strong Buy69
out of 100
Grade: B-
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+1.2%
Fair Value
$70.62
Current Price
$69.78
$0.84 discount
Margin of Safety
+65.3%
Fair Value
$94.54
Current Price
$25.68
$68.86 discount
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Large-cap with strong market position
Growing faster than its price suggests
15.9% revenue growth
Generating 1.0B in free cash flow
Every $100 of equity generates 26 in profit
Growing faster than its price suggests
Attractively priced relative to earnings
Reasonable price relative to book value
Earnings expanding 35.8% YoY
Areas to Watch
Premium valuation, high expectations priced in
Distress zone — elevated risk
Elevated debt levels
Comparative Analysis Report
WallStSmart ResearchBull Case : BSX
The strongest argument for BSX centers on Market Cap, PEG Ratio, Revenue Growth. Revenue growth of 15.9% demonstrates continued momentum. PEG of 0.75 suggests the stock is reasonably priced for its growth.
Bull Case : CUK
The strongest argument for CUK centers on Return on Equity, PEG Ratio, P/E Ratio. PEG of 0.84 suggests the stock is reasonably priced for its growth.
Bear Case : BSX
The primary concerns for BSX are P/E Ratio.
Bear Case : CUK
The primary concerns for CUK are Altman Z-Score, Debt/Equity. Debt-to-equity of 2.28 is elevated, increasing financial risk.
Key Dynamics to Monitor
BSX profiles as a growth stock while CUK is a value play — different risk/reward profiles.
CUK carries more volatility with a beta of 2.46 — expect wider price swings.
BSX is growing revenue faster at 15.9% — sustainability is the question.
BSX generates stronger free cash flow (1.0B), providing more financial flexibility.
Bottom Line
CUK scores higher overall (69/100 vs 63/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Boston Scientific Corp
HEALTHCARE · MEDICAL DEVICES · USA
Boston Scientific Corporation, doing business as Boston Scientific, is a manufacturer of medical devices used in interventional medical specialties, including interventional radiology, interventional cardiology, peripheral interventions, neuromodulation, neurovascular intervention, electrophysiology, cardiac surgery, vascular surgery, endoscopy, oncology, urology and gynecology.
Carnival Plc ADS
CONSUMER CYCLICAL · TRAVEL SERVICES · USA
Carnival Corporation & plc is a leisure travel company. The company is headquartered in Miami, Florida.
Visit Website →Compare with Other MEDICAL DEVICES Stocks
Want to dig deeper into these stocks?